Roll No. Total No. of Pages: 02

Total No. of Questions: 13

# B.Pharmacy (Sem.-8) PHARMACEUTICAL REGULATORY SCIENCE

Subject Code: BP804ET M.Code: 79767

Date of Examination: 06-01-2023

Time: 3 Hrs. Max. Marks: 75

#### **INSTRUCTIONS TO CANDIDATES:**

- SECTION-A is COMPULSORY consisting of TEN questions carrying TWO marks each.
- 2. SECTION-B contains THREE questions carrying TEN marks each and student has to attempt any TWO questions.
- 3. SECTION-C contains NINE questions carrying FIVE marks each and student has to attempt any SEVEN questions.

#### **SECTION-A**

# 1. Write briefly:

- a) What is meant by Phase-I studies?
- b) What is a generic product?
- c) What is a proprietary product?
- d) Name the regulatory authorities of India and USA.
- e) Mention the different types of DMFs.
- f) What is the purpose of micro dosing studies?
- g) What is meant by 'exclusion criteria' in clinical trials?
- h) What is 'orange book'?
- i) What is meant by 'informed consent'?
- j) What is meant by 'double blind trial'?

**1 | M-79767** (S29)-1573

## **SECTION-B**

- 2. Discuss the Indian regulations for export and import of pharmaceuticals.
- 3. Discuss the 'inclusion' and 'exclusion' criteria for anti-diabetic drug clinical trial.
- 4. What is ANDA? Discuss the regulatory requirements for filing ANDA.

### **SECTION-C**

- 5. Differentiate between NCE and Lead Molecule.
- 6. Differentiate between IND and ANDA.
- 7. Outline the process of developing a generic product.
- 8. What is the constitution and functions of Institutional Ethics Committee?
- 9. What is the constitution and purpose of IRB?
- 10. Comment on the process of obtaining consent of a volunteer for clinical trial.
- 11. Briefly discuss the process and modes of pharmacovigilance.
- 12. Comment on provisions contained in Schedule Y.
- 13. Write a note on eCTD.

NOTE: Disclosure of Identity by writing Mobile No. or Marking of passing request on any paper of Answer Sheet will lead to UMC against the Student.

**2 | M-79767** (S29)-1573